Trendy anti-aging biotech Unity adds $55M as it preps first human trial to flush senescent cells
Unity Biotechnology is filling up its cash reserves with another venture round before it goes into its first anti-aging human studies.
The Bay Area biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
